Adjusted analysis demonstrates lower controller inhaler use in Asian, Black, and Hispanic adults with #Asthma than in White adults, despite accounting for clinical, socioeconomic, and health care access factors. ja.ma/3PMQfIs

New simultaneous 📝 at #ATS2026 out in @jama.com: Disparities in Inhaler Utilization Among US Adults w. Asthma. The number to remember: 37%. Only 37% used inhaled corticosteroids (ICS), the cornerstone of guideline-based asthma treatment w large racial/ethnic gaps. jamanetwork.com/journals/jam...

This #PharmacoequityFriday I’m sharing new research from our team out this week in @jamanetworkopen.com. In a study of 1.6 million adults, we found that folks w. #AFib had >$11 K ⬆️ in annual medical costs (including nearly $2K ⬆️ for 💊💊) vs. those w/o AFib. 📝: jamanetwork.com/journals/jam...

A success story for a physician with Alzheimer's which, in spite of the obstacles outlined, is a precursor for our enhanced ability to prevent the disease in the future gift link www.wsj.com/opinion/i-ca...

Thrilled to hear @uressien.bsky.social at @dukemedschool.bsky.social speaking on Pharmacoequity

Glad to have contributed to this study examining #Pharmacoequity of newer disease modifying therapies for patients with rheumatoid arthritis. Take a look at our paper below! 📝: www.jrheum.org/content/52/1...

Pharmacoequity turned 4 years old last month! Had a wonderful time in Ann Arbor last week as this year’s McKesson Equity Series Speaker @ the University of Michigan College of Pharmacy sharing on the past, present, and future of this growing field. Let’s work together to achieve #Pharmacoequity! 💊

Had a wonderful time at the National Academy of Medicine (@nam.edu) Annual Meeting last week, kicking off Year 2 of the Emerging Leaders in Health and Medicine! ✨ Always great to connect with mentors, role models, and friends at this meeting and to celebrate the new inductees into the Academy.

Every Wednesday evening for years I’ve opened the @nejm.org weekly email to dozens of the latest clinical trials of exciting new therapies. Yet, the future diffusion and equitable dissemination & implementation of these drugs is FAR less studied. So many opportunities to advance #Pharmacoequity. 💊

Love the idea of a series focused on tobacco cessation globally, esp the role of #Pharmacoequity. 💊 But not sure there is evidence to support that it’s “lagging knowledge” driving ⬇️ rates of treatment in low and middle income countries. 🤔 Hoping for more data ahead. www.nejm.org/doi/full/10....

My patient recently lost his Medicaid insurance and couldn’t afford his meds. Just calculated the cost of his 13 💊 which would be $2300/month. That’s around $27,500/year. The FPL for a family of 4 is ~$32,000. This is not sustainable for the health and lives of our patients! #Pharmacoequity

Walked into a #RiteAid in CA yday that was EMPTY. Sad. “The hundreds of stores that are set to close within the year will limit many Americans' access to 💊 resulting in "pharmacy deserts"—less-connected communities being left w/o nearby drugstores. #Pharmacoequity www.newsweek.com/rite-aid-cvs...

In this week’s newsletter, we’re celebrating the well-deserved recognition our faculty and trainees have earned for their impact across education, research, clinical care, and community engagement. Read about the latest honors and achievements here: uclahs.fyi/3GZDVQQ

What an outstanding @cudeptofmedicine.bsky.social grand rounds presentation by the inspiring @uressien.bsky.social ! #pharmacoequity "Pursuing Pharmacoequity: The Case of Atrial Fibrillation"

Sharing a short thread here on our recent publication from earlier this month. This project was an incredible team effort, and truly would not have been possible without every co-author on this all-⭐ team! Go give it a read here if interested: jamanetwork.com/journals/jam... A short 🧵: (1/x)

‼️ New Simultaneous 📝 at #SGIM25. In 2023, lecanemab became the 1st disease-modifying 💊 for Alzheimer’s disease. Led by 🌟 Frank Zhou, we found that early uptake of lecanemab still appears to be marked by racial, ethnic & socioeconomic disparities. jamanetwork.com/journals/jam... #Pharmacoequity

Congrats to the amazing, Renu! ✨

Pharmacoequity matters. Appreciate this work! #AGS25 @uressien.bsky.social

📋‼️Honored to share this newly published article that I helped lead! Cannot thank @uressien.bsky.social enough - he has served as a friend, mentor, and sponsor throughout! And the whole study team who this wouldn’t have happened without!🙏🏽 Will post a longer thread on the findings soon - stay tuned!

‼️ NEW Paper. Led by @sudkrishnamurthy.bsky.social we found wide disparities in receipt of ERBB2-targeted 💊 for Medicare enrollees w. breast cancer, disparities that did narrow by 2019. We need more research to identify strategies to improve cancer #Pharmacoequity. jamanetwork.com/journals/jam...

Our new editorial in JAMA Network Open: Lower rates of high-risk med use in minoritized Medicare beneficiaries may reflect access barriers, not better care. Highlights urgent need for equity in deprescribing practices & alternatives to PIMs. With @uressien.bsky.social jamanetwork.com/journals/jam...

In people with diabetes, GLP-1 and SGLT2i drugs were associated with less Alzheimer's disease and related dementias jamanetwork.com/journals/jam...

NEW Academic Achievement Unlocked: Fellow of the American College of Physicians! ✨😅 Grateful to Dr. Eileen Barrett for the nomination and to my Dad, the first and best internal medicine doctor I know. 🤎👨🏾‍⚕️ #FACP cc @gradydoctor.bsky.social

“…11% of people said they could not afford medication and care within the past 3 months, the highest level in the four years the survey has been conducted. Over 1/3 said if they were to need medical care, they would not be able to pay for it.” #Pharmacoequity www.nytimes.com/2025/04/02/h...

"In labs around the world, scientists are using A.I. to search among existing medicines for treatments that work for rare diseases." And saving some lives. @davidfajgenbaum.bsky.social gift link www.nytimes.com/2025/03/20/w...

Sharing my new JAMANetworkOpen study, showing disparities in patient-clinician communication experiences of adults with/without serious illness: jamanetwork.com/journals/jam.... Compared to those without, adults with serious illness were more likely to feel afraid to ask questions, 1/

99% of new medicines developed by the pharmaceutical industry depend on NIH research jamanetwork.com/journals/jam...

Had the pleasure of being invited (virtually) to both the University of Iowa College of Medicine and College of Dentistry to serve as a Distinguished Lecturer. 🖤💛 We need more than just talk right now to bring us closer to justice in health, but hoping to help inspire the future.

Such a treat to have my friend and LEADER, Dr. Jasmine Marcelin, as our Department of Medicine Grand Rounds speaker. 👩🏾‍⚕️ Her talk, “Antimicrobial Prescribing Disparities and the Pursuit of #Pharmacoequity” was data-filled and inspiring. ✨

Thanks to the *105-year-old* UCLA campus newspaper, the Daily Bruin, for this feature. 🗞️🐻 #HealthEquity dailybruin.com/2025/01/20/q...

HHS announces the next 15 drugs to negotiate under Part D! Great to see this progress. Quite a few cancer treatments, which will mean more savings potential than in the first year's drug list (cancer drugs get limited or no rebates today). Good news for taxpayers and Medicare spending!

NEW: The next 15 drugs chosen for Medicare price negotiation have been announced by the administration. 💊 Perhaps unsurprisingly but importantly, the list includes Ozempic and Wegovy. #Pharmacoequity apple.news/Ah_4w14VjRgS...

NEW: "Things will get worse before they get better" and "We're not giving up." Reactions to today's data showing medical school enrollments dropped steeply for Black, Hispanic, and Indigenous applicants. With @uressien.bsky.social @roxanadaneshjou.bsky.social www.statnews.com/2025/01/09/m...

After acknowledging the fact that we both packed evacuation bags yday, spoke w. @usha.bsky.social about the new data on med school enrollment. “The number of Black enrollees fell by 11.6%… Hispanic enrollees ⬇️ 10.8%… American Indian or Alaska Natives ⬇️ by 22.1%.” www.statnews.com/2025/01/09/m...

New study in JACC EP suggests no White vs. Black difference in the risk of device-detected #AFib. More data to seemingly debunk the “racial paradox” around AFib. Ealier AFib detection for ALL patients may help to eliminate wide stroke disparities. 📝: www.sciencedirect.com/science/arti...

Homelessness has increased 18% in the US over the past year-with increases in family homelessness as well as for people who have been homeless for the first time. Veteran homelessness - an area for which there has been intentional investment - is down. apnews.com/article/home...

Nice overview in the American Journal of Health-System Pharmacy on how pharmacists can incorporate #Pharmacoequity into the formulary review process… …This will help ensure that the needs of vulnerable patient populations are being considered & addressed. academic.oup.com/ajhp/advance...

Excited to share the publication of my 1st research article from my dissertation work in @alzdemjournals #DADM! Go give it a read here: alz-journals.onlinelibrary.wiley.com/doi/full/10.... A short 🧵 (1/x)

This is going to save hospitals a lot of money ! www.pennmedicine.org/news/news-re...

Thanks to Mt. Sinai Department of Medicine and Med-Peds for the invitation to the Dr. Arnold Drapkin Memorial Lectureship today. ✨ Enjoyed being back home in NY.🗽 #Pharmacoequity

New study describing antibiotic prescribing variation for children in the hospital. #Pharmacoequity 💊

New Position Statement from the American Academy of Allergy, Asthma, & Immunology highlighting the importance of #Pharmacoequity in the field of food allergy. 💊 Really exciting to see this concept expanding! secure.jbs.elsevierhealth.com/action/getSh...

New app. Same vibes. ✈️ Excited for #AHA24! Looking forward to sharing our latest #AFib work and presenting on #Pharmacoequity with an all-⭐️ team @ the ABC Symposium. But mostly ready to reconnect with friends & colleagues in the Chi. 💨 See y’all soon. 👊🏾